A tree that makes a rare anticancer compound is near extinction. Chinese scientists may have an answer
- As critical yew tree becomes scarce, Chinese study finds new pathway to rare anticancer compound
- Research on the plant that produces cigarettes offers new hope in the treatment of breast, ovarian and lung cancer
But despite the success of paclitaxel in clinical applications, it is extremely difficult to obtain. It makes up only about 0.004 per cent of the tree’s bark.
The scarcity means that treating a patient with ovarian cancer, for instance, requires between three to 12 yew trees that are more than a century old, resulting in large numbers of yew trees being cut down.
New Chinese drug shows record treatment success against deadly lung cancer type
The effectiveness and rarity of the tree has led to extensive research into alternative and sustainable production methods, including semi-synthesis from intermediates and cultivation of plant cell cultures that could reduce the need to cut down yew trees.
The chemical structure of paclitaxel, however, is extremely complex. Missing knowledge about the genes involved in several steps of paclitaxel’s biosynthesis has made it difficult to engineer the full pathway.
There may be a way around those challenges, thanks to the insights of two Chinese professors. Yan Jianbin with Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, and Lei Xiaoguang with the College of Chemistry and Molecular Engineering at Peking University, have suggested a new understanding of the synthesis pathway of paclitaxel.
US$280 in China, US$8,892 in the US: new Chinese cancer drug gets FDA approval
The researchers were able to artificially constitute a biosynthetic pathway for the key precursor of paclitaxel in tobacco. Their findings were published in the peer-reviewed journal Science on Thursday.
“The reaction steps [to produce paclitaxel] can be divided into three critical processes, including the formation of a skeleton, the biosynthesis of a highly functionalised intermediates called baccatin III based on the skeleton, and the attachment of a side chain,” Yan said in the paper.
The final step may be the most elusive. While it has been widely investigated for half a century, the complete biosynthetic pathway of baccatin III remained a mystery.
Then, the team found a distinctive chemical logic in the formation of a core structure called the “oxetane ring” and proved the process could be realised in a tobacco plant.
Biosynthesis of baccatin III typically requires at least 13 enzymes. But after the researchers introduced two key enzymes, they were able to cut the number of enzymes needed for the biosynthesis to nine.
What made the two key enzymes special is their versatility – a quality called functional promiscuity – meaning a single enzyme might catalyse several reactions at the same time.
Yan and his team investigated further, trying to determine if those nine genes formed the critical pathway that creates baccatin III.
“We attempted to co-express the two new genes with other known genes involved to determine whether we can artificially reconstruct the biosynthesis pathway in tobacco,” Yan said in the paper.
“Results show baccatin III could hardly be detected when any of the nine genes were absent. The outcome indicates that the nine genes constitute the core pathway in baccatin III biosynthesis. Some enzymes that were previously thought important might be unnecessary” he added.
09:24
Cancer cure? Hong Kong develops ‘world’s first’ treatment to reverse stage-four liver cancer
The research offers a path through a stubborn bottleneck to biosynthesis of the precursor of paclitaxel. The pathway could be introduced into tobacco through gene engineering, which provides a chance for future production, according to researchers.
Yan said their future work would focus on clarifying the specific catalytic orders and versatility of the nine enzymes they had identified, as well as finding the rate that determines the steps for metabolic engineering optimisation.
The final challenge for researchers is to achieve batch manufacturing of paclitaxel. “With more effort from a broad field of scientists, including natural product chemists, plant physiologists, and synthetic biologists, green and efficient manufacturing of paclitaxel may be achieved via synthetic biology in the future,” Yan said the paper.
